Medical references of ambulatory BP monitoring

Medical references

In this section, we gathered some medical references about ambulatory blood pressure monitoring. You can find all the abstracts of these references below.

Eoin O’Brien, Roland Asmar, Lawrie Beilin, Yutaka Imai, Jean-Michel Mallion,Giuseppe Mancia, Thomas Mengden, Martin Myers, Paul Padfield,Paolo Palatini, Gianfranco Parati, Thomas Pickering, Josep Redon, Jan Staessen, George Stergiou and Paolo Verdecchia, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring:
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement
The “ESH recommendations” is a reference source for other guidelines relating to hypertension and cardiovascular disease. Analyses main factors to be taken into consideration when choosing the appropriate method of blood pressure measurement or selecting an accurate device. Introduces the procedure of blood pressure measurement by comparing conventional sphygmomanometry to ambulatory blood pressure measurement and self BP measurement.

Source: Journal of Hypertension 2003, 21:821–848

European guidelines on cardiovascular disease prevention in clinical practice: executive summary, Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Authors/Task Force Members, Ian Graham, Chairperson, Dan Atar, Knut Borch-Johnsen, Gudrun Boysen, Gunilla Burell, Renata Cifkova, Jean Dallongeville, Guy De Backer, Shah Ebrahim, Bjørn Gjelsvik, Christoph Herrmann-Lingen, Arno Hoes, Steve Humphries, Mike Knapton, Joep Perk, Silvia G. Priori, Kalevi Pyorala, Zeljko Reiner, Luis Ruilope, Susana Sans-Menendez, Wilma Scholte op Reimer, Peter Weissberg, David Wood, John Yarnell and Jose Luis Zamorano
The “Guidelines” aim to promote higher quality of care to help reduce the enormous burden of CVD and CVD in Europe. It contains prevention strategies and policy issues giving the highest priority to individuals at highest CVD risk. Gives detailed analysis of all risk factors, with increased attention on exercise, weight, lifestyle, risk in the young, gender issues, heart rate, renal impairment, etc.

Source: European Heart Journal 2007 28(19):2375-2414; doi:10.1093/eurheartj/ehm316

Eoin O’Brien:
Is the Case for ABPM as a Routine Investigation in Clinical Practice Not Overwhelming?

The most common use of ABPM devices and the only one for which reimbursement is approved in the USA is suspected white coat hypertension, however, the appropriation and diagnostic possibilities of these devices are much wider than that...

S. Allender, P.Scarborough, V. Peto, M. Rainer, j. Leal, R. Luengo-Fernandez, A. Gray:

Source : European cardiovascular disease statistics 2008, British Heart Foundation

C. Zoccali, F. Mallamaci, G. Tripepi:
Hypertension as a Cardiovascular Risk Factor in End-Stage Renal Failure.
Current Hypertension Reports. 2002. Vol. 4. No. 5.

The relationship between the predialysis systolic, diastolic and pulse pressure and left ventricular mass is much stronger than that between the corresponding postdialysis values and left ventricular mass.

T. Mengden, H. Vetter, E. Tousset, S. Uen:
Management of patients with uncontrolled arterial hypertension – the role of electronic compliance monitoring, 24 h blood pressure monitoring and Candesartan/HCT

“Incomplete drug regimen compliance (DRC) and white-coat hypertension are two of several possible causes of uncontrolled hypertension. Therefore the aim of the present study was to compare DRC in hypertensives treated with combination therapy whose blood pressures (BP) were controlled vers. uncontrolled after 4 weeks of self-monitored BP measurement. To observe the consequences in uncontrolled patients of switching one drug of the combination therapy to candesartan/HCTZ (16 mg/12.5 mg) with and without a compliance intervention program.
Methods: Self-and ambulatory-monitoring of BP were done with upper arm oscillometric devices.”

Source: BMC Cardiovascular Disorders 2006, 6:36
© 2006 Mengden et al; licensee BioMed Central Ltd.

P. Verdecchia:
Prognostic Value of Ambulatory Blood Pressure: Current Evidence and Clinical Implications

A critical article of the available evidence on the prognostic value of ambulatory blood pressure.

Source: Hypertension 2000; 35; 844-851

Wang YR, Alexander GC, Stafford RS.:
Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States.

The comparison showed that BP levels were lower and hypertension control was better in the United States than in the examined 5 Western European countries – this may be explained by more intensive treatment guidelines of the United States (lower treatment thresholds, more intensive treatment).

Source: Arch Intern Med. 2007; 167:141-147.

J. F. Reckelhoff, L. A. Fortepiani:
Novel Mechanisms Responsible for Postmenopausal Hypertension

The review discusses some of the possible mechanisms that could play a role in postmenopausal hypertension as well as the characteristics of an aging female spontaneously hypertensive rat – a model to study.

Source: Hypertension 2004; 43; 918-923

10.

B. Pilz, J-H. Brasen, W. Schneider, F. C. Luft:
Obesity and Hypertension-Induced Restrictive Cardiomyopathy: A Harbinger of Things to Come

Source: Hypertension, 2004; 43; 911-917

11.

Freitag, Michael H.; Vasan, Ramachandran S.:
What is Normal Blood Pressure?

Optimal blood pressure is 115/75 mmHg because it is associated with minimal vascular mortality. The target blood pressure goal for treated hypertensives is 140/90mmHg.

Source: Current Opinion in Nephrology and Hypertension: May 2003 - Volume 12 - Issue 3 - pp 285-292

12.

Mancia G., Volpe R., Boros S., Ilardi M., Giannattasio C.:
Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care.

The occurance of hypertension in Italy is usually associated with metabolic risk factors and frequently with a high or very high cardiovascular risk profile.

Source: Journal of Hypertension 2004;22:51-57.

13.

Sever, P, Dahlöf B, Poulter N Hans Wedel, Gareth Beevers, Mark Caulfield, Rory Collins, Sverre Kjeldsen, Arni Kristinsson, Gordon McInnes, Jesper Mehlsen, Markku Nieminem, Eoin O'Brien, Jan Östergre on behalf of the ASCOT Steering Committee Members.
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.

The objective of the ASCOT trial was to assess whether any synergistic effects were apparent between the atorvastatin and an amlodipine-based regimens in the prevention of CHD events.

Source: European Heart J, 2006; 27:2982-2988.

14.

Aram V. Chobanian, MD; George L. Bakris, MD; Henry R. Black, MD; William C. Cushman, MD; Lee A. Green, MD, MPH; Joseph L. Izzo, Jr, MD; Daniel W. Jones, MD; Barry J. Materson, MD, MBA; Suzanne Oparil, MD; Jackson T. Wright, Jr, MD, PhD; Edward J. Roccella, PhD, MPH; and the National High Blood Pressure Education Program Coordinating Committee
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 Report
A guideline for hypertension prevention and management, including: 1. importance of systolic blood pressure in individuals over 50; 2. the risk of CVD; risk of normotensive 55 year old individuals to develop hypertension; 3. definition of prehypertensive individuals; 4. drug treatment indications for patients with uncomplicated hypertension; 5. 2 or more required antihypertensive medications to achieve goal BP; 6. if BP is above goal BP...; 7. motivation of patients is essential

Source: JAMA. 2003;289:(doi:10.1001/jama.289.19.2560).

15.

Pickering T, Schwartz J, Verdecchia P, Imai Y, Kario K, Eguchi K, Pierdomenico S, Ohkubo T, Wing L:
Prediction of strokes versus cardiac events by ambulatory monitoring of blood pressure: results from an international database.
The study examines the role of nighttime versus daytime ambulatory blood pressure in predicting stroke and cardiac events. Evaluation of events went on for an average of 5.8 years.

Source: Blood Press Monit. 2007 Dec;12(6):397-9.

16.

Bakris G, Hill M, Mancia G, Steyn K, Black HR, Pickering T, De Geest S, Ruilope L, Giles TD, Morgan T, Kjeldsen S, Schiffrin EL, Coenen A, Mulrow P, Loh A, Mensah G:
Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action.
A Working Group of nine international health-care organizations reviewed the barriers to more effective blood pressure control and proposed actions to address them.

Source: J Hum Hypertens. 2008 Jan;22(1):63-70. Epub 2007 Aug 30.

17.
Barna, A. Keszei, A. Dunai:
Evaluation of Meditech ABPM-04 ambulatory blood pressure measuring device according to the British Hypertension Society protocol.

Source: Blood Press Monit. 1998;3(6):363-8.

18.

I. Barna:
Treatment of hypertension associated with prediabetes
In patients with hypertension associated with prediabetes, change of life style and metabolically neutral antihypertensive medication is the most effective treatment.

Source:
Orv Hetil. 2009 May 17;150(20):917-23

19.

Athanase Benetos; Patrick Lacolley:
From 24-Hour Blood Pressure Measurements to Arterial Stiffness. A Valid Short Cut?
An editorial commentary in Hypertension (Journal of the American Heart Association) recommending studies that are novel in showing that the AASI may be complementary to PP in the evaluation of cardiovascular risk and could be a more sensitive predictor of stroke, especially in low risk patients.

20.

Stanley S. Franklin, MD; Martin G. Larson, ScD; Shehzad A. Khan, BS; Nathan D. Wong, PhD; Eric P. Leip, MS; William B. Kannel, MD; Daniel Levy, MD:
Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging? The Framingham Heart Study.
A study involving 6539 men and women between 20 and 79 years of age freeof CHD and antihypertensive therapy – with increasing age a gradual shift was shown from DBP to SBP and then to PP.

21.

Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK:
The progression from hypertension to congestive heart failure.
The objective was to study the risks of hypertension for the development of CHS, to assess the time course of progression and to identify risk factors.

Source: JAMA. 1996 May 22-29;275(20):1557-62.

22.

Kannel WB:
Blood pressure as a cardiovascular risk factor: prevention and treatment.
The aim of the study was to examine the prevalence, incidence and predisposing factors for hypertension – the results showed that it is one of the most prevalent and powerful contributors to cardivascular diseases, thus the leading cause of death in the United States.

Source: JAMA - 22-MAY-1996; 275(20): 1571-6

Link sources:

Medical references of ambulatory BP monitoring

http://www.bhsoc.org/

http://eurheartj.oxfordjournals.org/ 1

http://eurheartj.oxfordjournals.org/ 2

http://hyper.ahajournals.org/

http://hyper.ahajournals.org/ 2

http://hyper.ahajournals.org/ 3

http://hyper.ahajournals.org/ 4

http://hyper.ahajournals.org/ 5

http://www.heartstats.org/ 1